长效GnRH激动剂方案提高正常反应者新鲜胚胎移植周期活产率但不提高累积活产率:一项随机对照试验及分子机制研究
该前瞻性随机对照试验纳入819例正常卵巢反应的不孕女性,比较GnRH拮抗剂、长效GnRHa和长方案GnRHa三种控制性卵巢刺激方案的累积活产率,发现三组累积活产率相似,但长效GnRHa方案每次新鲜胚胎移植的活产率显著更高,且子宫内膜容受性标志物表达更高。
要点
- 三种方案一次完整ART周期的累积活产率相似:拮抗剂组71.4%、长效GnRHa组75.5%、长方案组72.2%。
- 长效GnRHa方案新鲜胚胎移植周期活产率显著高于长方案和拮抗剂方案(62.6% vs 52.1% vs 45.6%,P < 0.05)。
- 长效GnRHa方案子宫内膜HOXA10、MEIS1和LIF的mRNA和蛋白表达均显著高于其他两方案(P < 0.05)。
核心结论
- 长效GnRH激动剂方案提高正常反应者每次新鲜胚胎移植周期的活产率,但不提高累积活产率。
研究设计与样本
- 前瞻性对照、随机、开放标签试验,于2016年5月至2017年5月进行,819例正常卵巢反应的不孕女性按1:1:1随机分配至GnRH拮抗剂、长效GnRHa或长方案GnRHa方案。
- 从首次IVF周期起最短随访时间为2年。
- 分子机制研究纳入34例子宫内膜活检患者,在取卵后或自然周期自发排卵后第7-8天采集内膜组织。
主要发现
- GnRH拮抗剂、长效GnRHa和长方案GnRHa三组的累积活产率分别为71.4%、75.5%和72.2%,无显著差异。
- 长效GnRHa方案新鲜胚胎移植周期活产率为62.6%,显著高于长方案GnRHa的52.1%和GnRH拮抗剂的45.6%(P < 0.05)。
- 长效GnRHa方案子宫内膜HOXA10、MEIS1和LIF的mRNA和蛋白表达均显著高于长方案GnRHa和GnRH拮抗剂方案(P < 0.05)。
临床怎么用
- 作者认为长效GnRH激动剂方案提高新鲜胚胎移植周期活产率,但不提高累积活产率;新鲜胚胎移植后活产率提高的可能解释是子宫内膜容受性层面的分子信号。
局限性
- 随机对照试验中临床医生和患者均未对随机分组设盲。
- 当前回顾性队列研究的纳入标准基于控制性卵巢刺激治疗期间的「实际卵巢反应」,而随机对照试验纳入人群为基于母亲年龄和卵巢储备试验的「预期正常反应者」。
- 分析仅限于40岁以下接受首次IVF周期的患者。
- 子宫内膜组织采集自取消新鲜胚胎移植的患者,可能包括部分存在卵巢过度刺激综合征风险的患者,但分子研究仅纳入获卵数4-19个的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do cumulative live birth rates (CLBRs) after one complete ART cycle differ between the three commonly used controlled ovarian stimulation (COS) protocols (GnRH antagonist, depot GnRHa (GnRH agonist) and long GnRHa) in normal responders undergoing IVF/ICSI? SUMMARY ANSWER: There were similar CLBRs between the GnRH antagonist, depot GnRHa and long GnRHa protocols. WHAT IS KNOWN ALREADY: There is no consensus on which COS protocol is the most optimal in women with normal ovarian response. The CLBR provides the final success rate after one complete ART cycle, including the fresh and all subsequent frozen-thawed embryo transfer (ET) cycles. We suggest that the CLBR measure would allow for better comparisons between the different treatment protocols. STUDY DESIGN, SIZE, DURATION: A prospective controlled, randomized, open label trial was performed between May 2016 and May 2017. A total of 819 patients were allocated to the GnRH antagonist, depot GnRHa or long GnRHa protocol in a 1:1:1 ratio. The minimum follow-up time from the first IVF cycle was 2 years. To further investigate the potential effect of COS with the GnRH antagonist, depot GnRHa or long GnRHa protocol on endometrial receptivity, the expression of homeobox A10 (HOXA10), myeloid ecotropic viral integration site 1 (MEIS1) and leukemia inhibitory factor (LIF) endometrial receptivity markers was evaluated in endometrial tissue from patients treated with the different COS protocols. PARTICIPANTS/MATERIALS, SETTING, METHODS: Infertile women with normal ovarian response (n = 819) undergoing IVF/ICSI treatment were randomized to the GnRH antagonist, depot GnRHa or long GnRHa protocol. Both IVF and ICSI cycles were included, and the sperm samples used were either fresh or frozen partner ejaculates or frozen donor ejaculates. The primary outcome was the live birth rate (LBR) per fresh ET cycle, and the CLBR after one complete ART cycle, until the birth of a first child (after 28 weeks) or until all frozen embryos were used, whichever occurred first. Pipelle endometrial biopsies from 34 female patients were obtained on Days 7-8 after oocyte retrieval or spontaneous ovulation in natural cycles, respectively, and HOXA10, MEIS1 and LIF mRNA and protein expression levels in the human endometrium was determined by quantitative real-time PCR and western blot, respectively. MAIN RESULTS AND THE ROLE OF CHANCE: There were no significant differences in CLBRs between the GnRH antagonist, depot GnRHa or long GnRHa protocol (71.4 versus 75.5 versus 72.2%, respectively). However, there was a significantly higher LBR per fresh ET cycle in the depot GnRHa protocol than in the long GnRHa and GnRH antagonist protocols (62.6 versus 52.1% versus 45.6%, P < 0.05). Furthermore, HOXA10, MEIS1 and LIF mRNA and protein expression in endometrium all showed significantly higher in the depot GnRHa protocol than in the long GnRHa and GnRH antagonist protocols (P < 0.05). LIMITATIONS, REASONS FOR CAUTION: A limitation of our study was that both our clinicians and patients were not blinded to the randomization for the randomized controlled trial (RCT). An inclusion criterion for the current retrospective cohort study was based on the 'actual ovarian response' during COS treatment, while the included population for the RCT was 'expected normal responders' based on maternal age and ovarian reserve test. In addition, the analysis was restricted to patients under 40 years of age undergoing their first IVF cycle. Furthermore, the endometrial tissue was collected from patients who cancelled the fresh ET, which may include some patients at risk for ovarian hyperstimulation syndrome, however only patients with 4-19 oocytes retrieved were included in the molecular study. WIDER IMPLICATIONS OF THE FINDINGS: The depot GnRH agonist protocol improves the live birth rate per fresh ET cycle, but not the cumulative live birth rate in normal responders. A possible explanation for the improved LBR after fresh ET in the depot GnRHa protocol could be molecular signalling at the level of endometrial receptivity. STUDY FUNDING/COMPETING INTEREST(S): This project was funded by Grant 81571439 from the National Natural Sciences Foundation of China and Grant 2016YFC1000206-5 from the National Key Research & Development Program of China. The authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: The RCT trial was registered at the Chinese Clinical Trial Registry, Study Number: ChiCTR-INR-16008220. TRIAL REGISTRATION DATE: 5 April 2016. DATE OF FIRST PATIENT’S ENROLLMENT: 12 May 2016.
引用
- Xu B, Geerts D, Hu S, et al. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study. Hum Reprod. 2020. PMID: 32478400. doi:10.1093/humrep/deaa086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。